Petros Kampanis

Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies

E. Soares, Vania Tietsche de Moraes Hungria, S. Allen, 2016, Revista brasileira de hematologia e hemoterapia.

A novel site of AKT‐mediated phosphorylation in the human MDM2 onco‐protein

F. Fuller-Pace, S. Nicol, D. Meek, 2004, FEBS letters.

Development and validation of an improved test for the measurement of human faecal elastase-1

J. Berg, L. Ford, Petros Kampanis, 2009, Annals of clinical biochemistry.

Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study

M. Taal, I. Dasgupta, Latha Gullapudi, 2020, PLoS medicine.

Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

I. Olafsson, P. T. Onundarson, B. Agnarsson, 2021, Blood.

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

I. Olafsson, P. T. Onundarson, B. Agnarsson, 2021, Blood Cancer Journal.

Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

I. Olafsson, P. T. Onundarson, B. Agnarsson, 2021, Blood.

Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research - the Importance of Screening: Results from the Population-Based Screening Study Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM)

I. Olafsson, P. T. Onundarson, B. Agnarsson, 2021, Blood.

Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies

G. T. Gunnarsson, Andri S. Björnsson, I. Olafsson, 2021, Blood Cancer Journal.